Dermatology leader Doncker is new Onicor CEO
pharmafile | October 29, 2026 | Appointment | |Â Â Dermatology, Infections and infestations, appointments, fungal infectionÂ
Onicor, a medical technology company developing a personalised treatment for onychomycosis (fungal nail infection), has appointed Piet De Doncker as its new Chief Executive Officer.
He succeeds co-founder Ronald van der Geest, PhD, who led the company from its inception and will continue to support the research of Onicor.
De Doncker has more than three decades of experience in antifungal and dermatology drug development. At Janssen Research & Development in Beerse, Belgium, now part of Johnson & Johnson, he played a leading role in developing itraconazole pulse therapy for onychomycosis, a one-week-per-month oral dosing regimen that became a widely used treatment option for fungal nail infections.
Related Content
Sanofi axes four major players from its executive committee
Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief …
Dr Richard Torbett is named as the new Chief Executive of the ABPI
The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its …
Insys Therapeutics names current CFO Andrew Long as company’s new CEO
Insys Therapeutics has said Andrew Long will take over from Saeed Motahari as the company’s …
